학술논문

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial
Document Type
Article
Author
Dimopoulos, Meletios AGay, FrancescaSchjesvold, FredrikBeksac, MeralHajek, RomanWeisel, Katja ChristinaGoldschmidt, HartmutMaisnar, VladimirMoreau, PhilippeMin, Chang KiPluta, AgnieszkaChng, Wee-JooKaiser, MartinZweegman, SonjaMateos, Maria-VictoriaSpencer, AndrewIida, ShinsukeMorgan, GarethSuryanarayan, KaveriTeng, ZhaoyangSkacel, TomasPalumbo, AntonioDash, Ajeeta BGupta, NeerajLabotka, RichardRajkumar, S VincentBar, DanielBasso, AlfredoFantl, DoroteaHe, SimonHorvath, NeomiLee, CindyRowlings, PhillipTaylor, KerrySpencer, AndrewCochrane, TaraKwok, FionaRamanathan, SundreswranAgis, HermineZojer, NiklasKentos, AlainOffner, FritzVan Droogenbroeck, JanWu, Ka LungMaiolino, AngeloMartinez, GraciaZanella, KarlaCapra, MarceloAraújo, SérgioGregora, EvzenHajek, RomanMaisnar, VladimirPour, LudekScudla, VlastimilSpicka, IvanAbildgaard, NielsAndersen, NielsJensen, Bo AmdiHelleberg, CarstenPlesner, TorbenSalomo, MortenSvirskaite, AstaDelarue, RichardMoreau, PhilippeBlau, IgorGoldschmidt, HartmutSchieferdecker, AnetaTeleanu, VeronicaMunder, MarkusRöllig, ChristophSalwender, Han-JuergenFuhrmann, StephanWeisel, KatjaDuerig, JanZeis, MatthiasKlein, StefanReimer, PeterSchmidt, ChristianScheid, ChristofMayer, KarinHoffmann, MartinSosada, MarkusDimopoulos, AthanasiosDelimpasi, SosanaKyrtsonis, Mary-ChristineAnagnostopoulos, AchilleasNagy, ZsoltIllés, ÁrpádEgyed, MiklósBorbényi, ZitaMikala, GaborDally, NajibHorowitz, NetanelGutwein, OditNemets, AnatolyVaxman, IulianaShvetz, OlgaTrestman, SvetlanaRuchlemer, RosaNagler, ArnonTadmor, TamarRouvio, OryPreis, MeirGay, FrancescaCavo, MicheleDe Rosa, LucaMusto, PellegrinoCafro, AnnaTosi, PatriziaOffidani, MassimoCorso, AlessandroRossi, GiuseppeLiberati, Anna MarinaBosi, AlbertoSuzuki, KenshiIida, ShinsukeNakaseko, ChiakiIshikawa, TakayukiMatsumoto, MorioNagai, HirokazuSunami, KazutakaChou, TakaakiAkashi, KoichiTakezako, NaokiHagiwara, ShotaroEom, Hyeon SeokJo, Deog-YeonKim, Jin SeokLee, Jae HoonMin, Chang KiYoon, Sung SooYoon, Dok HyunKim, KihyunZweegman, SonjaLevin, Mark-DavidVellenga, EdoMinnema, MoniqueSchjesvold, FredrikWaage, AndersHaukås, EinarGrosicki, SebastianPluta, AndrzejRobak, TadeuszMarques, HerlanderBergantim, RuiCampilho, FernandoChng, Wee JooGoh, Yeow TeeMcDonald, AndrewRapoport, BernadoÁlvarez Rivas, Miguel AngelDe Arriba de La Fuente, FelipeGonzález Montes, YolandaMartin Sanchez, JesusMateos, Maria VictoriaOriol Rocafiguera, AlbertRosinol, LauraSan Miguel, JesúsPérez de Oteyza, JaimeEncinas, CristinaAlegre-Amor, AdrianLópez-Guía, AnaAxelsson, PerCarlson, KristinaStromberg, OlgaHansson, MarkusHveding Blimark, CecileMueller, RouvenChen, Chih-ChengLiu, Ta-ChihHuang, Shang-YiWang, Po-NanNa Nakorn, ThanyaphongPrayongratana, KannaditBeksac, MeralUnal, AliGoker, HakanSonmez, MehmetKorenkova, SybirynaChaidos, AristeidisOakervee, HeatherSati, HamdiBenjamin, ReubenWechalekar, AshutoshGarg, MamtaKaiser, MartinRamasamy, KarthikCook, GordonChantry, AndrewJenner, MatthewBuadi, FrancisBerryman, RobertJanakiram, Murali
Source
The Lancet; January 2019, Vol. 393 Issue: 10168 p253-264, 12p
Subject
Language
ISSN
01406736; 1474547X
Abstract
Maintenance therapy following autologous stem cell transplantation (ASCT) can delay disease progression and prolong survival in patients with multiple myeloma. Ixazomib is ideally suited for maintenance therapy given its convenient once-weekly oral dosing and low toxicity profile. In this study, we aimed to determine the safety and efficacy of ixazomib as maintenance therapy following ASCT.